$Intensity Therapeutics (INTS.US)$ NEWS Intensity Therapeuti...
NEWS
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Positive
The collaboration agreement between Intensity Therapeutics, Inc. and SAKK for the Phase 2 clinical trial demonstrates the company's commitment to advancing its lead drug candidate, INT230-6.
INT230-6 has shown promising results in the first INVINCBLE-2 study, with over 95% necrosis in large breast cancer tumors and the induction of an immune response after a single dose.
Intensity Therapeutics aims to improve patients' pathological complete response (pCR) rates in early-stage triple-negative breast cancer by combining INT230-6 with standard of care, potentially leading to accelerated FDA approval.
Negative
The INVINCIBLE-4 Study results, expected in the second half of 2025, will determine the size of Phase 3 trials, indicating a longer timeline for potential market approval.
Potential adverse events and challenges related to the immune landscape and MRI predictive changes need to be carefully monitored and addressed during the study.
The collaboration agreement between Intensity Therapeutics, Inc. and SAKK for the Phase 2 clinical trial demonstrates the company's commitment to advancing its lead drug candidate, INT230-6.
INT230-6 has shown promising results in the first INVINCBLE-2 study, with over 95% necrosis in large breast cancer tumors and the induction of an immune response after a single dose.
Intensity Therapeutics aims to improve patients' pathological complete response (pCR) rates in early-stage triple-negative breast cancer by combining INT230-6 with standard of care, potentially leading to accelerated FDA approval.
Negative
The INVINCIBLE-4 Study results, expected in the second half of 2025, will determine the size of Phase 3 trials, indicating a longer timeline for potential market approval.
Potential adverse events and challenges related to the immune landscape and MRI predictive changes need to be carefully monitored and addressed during the study.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
840Followers
62Following
5577Visitors
Follow